Inclusion Criteria  Men and women age ≥ 18 to ≤ 70 years of age at the time of signing the informed consent Body mass index (BMI) of ≥ 27 kg/m2 to ≤ 45.0 kg/m2 Liver steatosis, measured by MRI-PDFF, greater than 8%  Exclusion Criteria  Evidence of other liver disease (eg, viral hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, autoimmune chronic hepatitis, Wilson's disease, alpha-1 anti-trypsin deficiency, haemochromatosis, drug-induced liver injury, bile duct obstruction, known or suspected hepatocellular carcinoma). Significantly elevated LFTs (more than 1.5x ULN) Uncontrolled diabetes (HgbA1c > 9%) or uncontrolled hypertension. History of malignancy of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers occurring more than 5 years prior to randomization or 3 years prior to randomization for basal cell carcinoma. Females of reproductive potential.